



ASX ANNOUNCEMENT

5 February 2024

NEW \$282K CONTRACT WITH MEDTRYX FOR PATIENT RECRUITMENT

Melbourne, Australia – Opyl Limited (ASX:OPL) is pleased to announce, its fully owned patient recruitment brand Opin has signed a new contract with Medtryx Pty Ltd, the local contractor for leading US-based biotechnology research group, Lumen Bioscience.

Key highlights

- Opin has secured a new contract with Medtryx Pty Ltd, the Australian contractor for US-based Lumen Bioscience
- Opin will support Medtryx using its digital patient recruitment platform, to recruit and onboard patients onto Lumen Bioscience's current etiological research study investigating Traveller's Diarrhoea
- Total contract value for Phase I is A\$282k to be delivered over a term of 15 months, with potential opportunity to extend support into later phases of the development program
- The agreement further validates Opin's revised strategy, noting this contract value is ~2.5x the average value of Opin's previous contracts

Medtryx is an Australian specialist clinical research organisation that supports the delivery of clinical trials and medical research programs across Asia Pacific. Globally, Medtryx has been involved in the executive oversight and clinical delivery of over 49 fully decentralised, direct-to-patient clinical trials since 2018.

The total contract value for Opyl is A\$282k and spans a 15-month period comprising a 3-month set-up stage and a subsequent 12-month recruitment process. Prior to securing the contract, Opin's average customer contract value was \$110k. The contract is subject to standard termination conditions for contracts of this nature.

Opyl will leverage its established digital expertise via its Opin platform and extensive clinical partnerships to facilitate the recruitment and onboarding of patients travelling to South-East Asia. The company will provide end-to-end recruiting services, including strategic planning, candidate screening and ongoing engagement optimisation with study participants. Importantly, Opin's unique capabilities were key to securing the contract, noting the recruitment platform's seamless digital experience as key to enabling Medtryx's to conduct the clinical study without the need to establish traditional clinical trial sites.

The agreement is of particular strategic value to Opyl, diversifying its customer base and presenting a range of strategic benefits including enhanced international brand awareness, further demonstration of platform value, and by providing various opportunities to collaborate directly with travel clinics and general practices.



Saurabh Jain, CEO of Opyl said:

"We are excited to have signed our contract with Medtrix and to be supporting Lumen. Both Medtrix and Lumen are strong partners for Opin, and we look forward to working with them over the coming months. This win shows the focus on revenue growth over the recent period which has also resulted in a healthy increase in our sales pipeline.

I'd like to thank the Opin team for their outstanding work".

The Board has authorised this announcement for release to the ASX.

-ENDS-

For investor enquiries:

Stefan Jacobs
Vesparum Capital
Phone: +61 3 8582 4800
Email: opyl@vesparum.com

For general enquiries:

Email: info@opyl.ai
Website: www.opyl.ai

About Opyl Limited

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials and predicting outcomes. Our platforms provide targeted insights that make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money. Our key offering for biopharma, medtech, government and healthcare organisations are Opin.ai (clinical trial recruitment solutions) and Trial Key (clinical trial predictive analytics and protocol design).